SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-279048
Filing Date
2020-10-28
Accepted
2020-10-28 06:05:32
Documents
15
Period of Report
2020-10-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d39557d8k.htm   iXBRL 8-K 28540
2 EX-99.1 d39557dex991.htm EX-99.1 19366
6 GRAPHIC g39557g1028034119855.jpg GRAPHIC 3841
7 GRAPHIC g39557img01.jpg GRAPHIC 5394
  Complete submission text file 0001193125-20-279048.txt   192137

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aeri-20201028.xsd EX-101.SCH 3094
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aeri-20201028_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aeri-20201028_pre.xml EX-101.PRE 11424
8 EXTRACTED XBRL INSTANCE DOCUMENT d39557d8k_htm.xml XML 3420
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36152 | Film No.: 201266006
SIC: 2836 Biological Products, (No Diagnostic Substances)